The JCOG 1008 trial exclusively studied cisplatin-eligible patients. Therefore, the weekly regimen should be seen as an alternative schedule for those who can tolerate cisplatin, not as a less toxic option to enable treatment for patients who are truly ineligible due to poor renal function, hearing loss, or other comorbidities.

The NIAGRA study used a creatinine clearance threshold of 40 ml/min for cisplatin, lower than the traditional 60 ml/min cutoff. This forward-looking design validates the practice of treating patients with borderline renal function with cisplatin, potentially allowing more individuals with MIBC to benefit from this chemotherapy.

Despite logistical challenges like clinic chair time, the ICON 8B study's positive results are forcing a re-evaluation of weekly paclitaxel. The trial demonstrated improved progression-free and overall survival compared to the standard three-week cycle, suggesting a potential shift back to a previously debated dose-dense strategy in the frontline setting.

A patient's disease stage fundamentally changes their risk calculus. In the metastatic setting, where the primary goal is survival, patients willingly endure significant toxicity as long as their cancer is controlled. In the adjuvant (curative) setting, the long-term impact of that same toxicity becomes a more critical factor.

The JCOG 1008 trial defined treatment completion as receiving at least five of seven planned weekly cisplatin doses (200 mg/m²). This provides clinicians with a practical, data-supported minimum target when managing patient toxicity, helping to balance efficacy against the need to push for all seven doses.

The ERA SAFE study found that a bi-weekly, lower-dose docetaxel regimen for triplet therapy significantly lowers grade 3-4 adverse events compared to the standard 3-week schedule. It reduced the risk of neutropenic fever from 5.5% to 1.7% while maintaining similar efficacy, offering a safer alternative for frail or vulnerable patients.

Clinicians emphasize that maintaining treatment continuity with a reduced, tolerable chemotherapy dose is superior to discontinuing therapy due to side effects. This approach helps patients stay on treatment longer, potentially improving overall survival.

In the JCOG 1008 trial, the weekly cisplatin arm had better outcomes despite a lower total drug dose. This suggests that maintaining consistent drug levels for radiosensitization throughout radiation is potentially more critical than the overall cumulative dose, which was higher in the less effective three-weekly arm.

The INTERACT trial showed carboplatin/paclitaxel had similar response rates and PFS to cisplatin/5-FU. It became the standard of care primarily due to its significantly better side effect profile, with lower rates of bone marrow suppression, fatigue, and GI toxicity.